Logo Image
|Videos|May 18, 2021

Addressing Roadblocks in Decentralized Trials

Author(s)Oracle

In a recent virtual roundtable discussion, industry experts Jim Streeter, Alison Holland, Hassan Kadhim, Craig Lipset, Josh Rose, and Craig Serra shared their insight on the challenges faced in implementing decentralized trials and how to address them. Along with the roundtable are video discussions covering the cost and feasibility of a toolkit approach to decentralized trials, the significance of minimizing burden to patients and sites, and the reality of regulatory hurdles.

Visit The Future of Clinical Trials to learn more about the methods and approaches that sponsors and clinical research organizations are employing to tackle the new challenges in the changing data landscape in decentralized clinical trials.


Oracle would like to thank the following participants:

Jim Streeter
Global Vice President
Life Sciences Product Strategy
Oracle Health Science

Alison Holland
Head of Decentralized Trials
Medable

Hassan Kadhim
Global Head of Clinical Trial Business Capabilities
Clinical Innovation & Industry Collaborations
Global Development Operations
Bristol Myers Squibb

Craig Lipset
Co-Founder
Decentralized Trials and Research Alliance

Josh Rose
VP and Global Head
IQVIA Decentralized Trials

Craig Serra
Clinical Technology and Innovation
Novartis

Related to this article

View more
Pharmaceutical Executive Daily
Pharmaceutical Executive Daily: FDA Approves Tecentriq
The FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new IPOs, and a Pharmaceutical Executive feature examines what it takes to turn precision medicine’s biological gains into deliverable therapies.
Read more
Naoki Okamura: Post-Patent Plan and Purpose
Naoki Okamura: Post-Patent Plan and Purpose
Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.
Read more